Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose intravenous immunoglobulin in idiopathic cardiomyopathy with cardiac parvovirus B19 persistence
2009-009463-61Phase 3Completed
- Sponsor
- Sanquin Plasma Products
- Start
- Apr 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic dilated cardiomyopathy (IDC) and erythema infectiosum comparing IVIg + conventional heart failure therapy with Placebo + conventional heart failure therapy (2 arms). Primary endpoint: Change in cardiac ejection fraction. Started Apr 2009; status: completed.
02
Drugs
immune globulin
03
Conditions
idiopathic dilated cardiomyopathy (IDC)erythema infectiosum
Beyond the preview
Go deeper on 2009-009463-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009463-61.